Despite a drop in earnings, Hubei Hongyuan Pharmaceutical's high P/E ratio suggests investors may be overly optimistic. Continued earnings trends could pose a risk to shareholders and potential investors.
Investors overlook the company's dismal growth, banking on business recovery. But enduring earning downturns may hurt the share price, making the high P/E ratio untenable.
宏源藥業股票討論區
暫無評論